Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of gastrectomy plus HIPEC to reduce peritoneal metastasis after curative surgery for gastric or gastroesophageal junction adenocarcinoma
2018-001433-41Phase 2Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and doxorubicin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by University Hospital Tübingen. Primary endpoints: Proportion of patients free from peritoneal metastasis at 1 year and Incidence of peritoneal metastases. Started Jan 2019; status: terminated.
02
Drugs
cisplatindoxorubicin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2018-001433-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001433-41.